Comparing keverprazan to the current standard of care for treating erosive esophagitis
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on September 19th, 2022
|
Proton pump inhibitors (PPI), such as lansoprazole, are usually prescribed to manage erosive esophagitis by increasing the pH of the gastric environment. However, the effectiveness of PPI is heavily dependent on which of the CYP2C19 polymorphic states that the patient possesses. A recent study looked at whether keverprazan, a potassium-competitive acid blocker that can suppress gastric acid production independently on the CYP2C19 liver enzyme, is as effective as the current standard of care.
The phase III clinical trial assigned 240 patients to either receive 20 mg of keverprazan daily or 30 mg of lansoprazole daily for 8 weeks. The participants were asked to report their symptoms at baseline, week 2, 4 and 8 after the trial had begun. Endoscopy is conducted to assess the esophagus lining at the last 2 visits and compare with baseline. The study found that keverprazan is non-inferior to lansoprazole in esophageal healing at the 4th and 8th week. And both groups reported that their symptoms, mostly heartburn and regurgitation, happens at a similar frequency. This similar rate of healing is observed between the two groups when the baseline severity is stratified. In terms of safety, abnormal liver function, hypertriglyceridemia, and hyperuricemia are the most commonly reported side effects. These drug-related adverse events are transient, and are reported at a similar frequency between the two treatment groups.
The phase III clinical trial assigned 240 patients to either receive 20 mg of keverprazan daily or 30 mg of lansoprazole daily for 8 weeks. The participants were asked to report their symptoms at baseline, week 2, 4 and 8 after the trial had begun. Endoscopy is conducted to assess the esophagus lining at the last 2 visits and compare with baseline. The study found that keverprazan is non-inferior to lansoprazole in esophageal healing at the 4th and 8th week. And both groups reported that their symptoms, mostly heartburn and regurgitation, happens at a similar frequency. This similar rate of healing is observed between the two groups when the baseline severity is stratified. In terms of safety, abnormal liver function, hypertriglyceridemia, and hyperuricemia are the most commonly reported side effects. These drug-related adverse events are transient, and are reported at a similar frequency between the two treatment groups.